
Multiple Myeloma Case Study: Refractory MM Patient: Efficacy with Immunomodulatory Therapy (Course Case Study 2232.06)
Published on June 30, 2015 Case Study
Expert Faculty: Sara Bringhen, MD, PhD
Medical Writer: Lisa M. Cimakasky, PhD
Published on June 30, 2015 Case Study
Expert Faculty: Sara Bringhen, MD, PhD
Medical Writer: Lisa M. Cimakasky, PhD
Click here to view our current activities in Oncology.
Patients with multiple myeloma (MM) who are refractory after two prior regimens have a poor prognosis. However, newer treatments provide effective options for these challenging patients. In this case study, Sara Bringhen, MD, PhD, discusses the importance of choice of treatment for an elderly patient with refractory MM.

Sara Bringhen, MD, PhD

Craig C. Hofmeister, MD, has received consulting fees from Celgene Corporation.
Philippe Moreau, MD, has received salary/honoraria and consulting fees from Celgene Corporation, Janssen Pharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, Inc., and Takeda.
Noopur Raje, MD, has received consulting fees from Amgen Inc., Celgene Corporation, Millennium Pharmaceuticals, Inc., and Onyx Pharmaceuticals, Inc.; and has conducted contracted research for Acetylon Pharmaceuticals, Inc. and Eli Lilly and Company.
Douglas W. Sborov, MD, has disclosed no relevant relationships.
Jatin J. Shah, MD, has received consulting fees from and has conducted contracted research for Array BioPharma, Celgene Corporation, Millennium Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Onyx Pharmaceuticals.
Ravi Vij, MD, has received consulting fees from and conducted contracted research for Bristol-Myers Squibb, Celgene Corporation, Millennium Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, Inc., and Sanofi.
Available for CME/CE:
Physicians
Publish Date: Jun 30, 2015 Termination Date: Jun 29, 2016Nurses
Publish Date: Jun 30, 2015 Termination Date: Jun 29, 2016Pharmacists
Publish Date: Jun 30, 2015 Termination Date: Jun 29, 2016Estimated time for completion of this activity:
Target Audience
This CME/CE program is intended for oncologists, hematologists, radiation oncologists, family practice/primary care physicians, nurse practitioners, physician assistants, and pharmacists involved in the management, treatment, and care of patients with multiple myeloma.
Activity Goal
The goal of this program is to offer meeting highlights, case-based studies, and webcast, at the point of care, to provide evidence-based data and strategies for diagnosing, treating, and managing patients with multiple myeloma.
Learning Objective (s)
- Formulate appropriate treatment regimens using immunomodulatory therapy for patients with refractory multiple myeloma.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Upon completion of this course, participants will be awarded 0.63 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This case study is worth up to 0.75 contact hour(s) (0.075 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-15-098-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that all those who have control of content comply with the Standards for Commercial Support. Faculty, planners, PIK editorial scientific team, reviewers, and medical writers are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed during the presentations.
Sara Bringhen, MD, PhD has disclosed no relevant relationships.
Peer Reviewer has disclosed no relevant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no relevant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no relevant relationships to disclose.
Lisa M. Cimakasky, PhD - medical writer, has disclosed no relevant relationships.
Projects In Knowledge's staff members have no relevant relationships to disclose.
Planning Committee
Sara Bringhen, MD, PhD has disclosed no significant relationships.
Craig C. Hofmeister, MD has received consulting fees from Celgene Corporation.
Philippe Moreau, MD has received salary/honoraria and consulting fees from Celgene Corporation, Janssen Pharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, Inc., and Takeda.
Noopur Raje, MD has received consulting fees from Amgen Inc., Celgene Corporation, Millennium Pharmaceuticals, Inc., and Onyx Pharmaceuticals, Inc.; and has conducted contracted research for Acetylon Pharmaceuticals, Inc. and Eli Lilly and Company.
Douglas W. Sborov, MD has disclosed no relevant relationships.
Jatin J. Shah, MD has received consulting fees from and has conducted contracted research for Array BioPharma, Celgene Corporation, Millennium Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Onyx Pharmaceuticals.
Ravi Vij, MD has received consulting fees from and conducted contracted research for Bristol-Myers Squibb, Celgene Corporation, Millennium Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, Inc., and Sanofi.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Jun 30, 2015 Termination Date: Jun 29, 2016Nurses
Publish Date: Jun 30, 2015 Termination Date: Jun 29, 2016Pharmacists
Publish Date: Jun 30, 2015 Termination Date: Jun 29, 2016Estimated time for completion of this activity:
Target Audience
This CME/CE program is intended for oncologists, hematologists, radiation oncologists, family practice/primary care physicians, nurse practitioners, physician assistants, and pharmacists involved in the management, treatment, and care of patients with multiple myeloma.
Activity Goal
The goal of this program is to offer meeting highlights, case-based studies, and webcast, at the point of care, to provide evidence-based data and strategies for diagnosing, treating, and managing patients with multiple myeloma.
Learning Objective (s)
- Formulate appropriate treatment regimens using immunomodulatory therapy for patients with refractory multiple myeloma.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Upon completion of this course, participants will be awarded 0.63 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This case study is worth up to 0.75 contact hour(s) (0.075 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-15-098-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that all those who have control of content comply with the Standards for Commercial Support. Faculty, planners, PIK editorial scientific team, reviewers, and medical writers are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed during the presentations.
Sara Bringhen, MD, PhD has disclosed no relevant relationships.
Peer Reviewer has disclosed no relevant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no relevant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no relevant relationships to disclose.
Lisa M. Cimakasky, PhD - medical writer, has disclosed no relevant relationships.
Projects In Knowledge's staff members have no relevant relationships to disclose.
Planning Committee
Sara Bringhen, MD, PhD has disclosed no significant relationships.
Craig C. Hofmeister, MD has received consulting fees from Celgene Corporation.
Philippe Moreau, MD has received salary/honoraria and consulting fees from Celgene Corporation, Janssen Pharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, Inc., and Takeda.
Noopur Raje, MD has received consulting fees from Amgen Inc., Celgene Corporation, Millennium Pharmaceuticals, Inc., and Onyx Pharmaceuticals, Inc.; and has conducted contracted research for Acetylon Pharmaceuticals, Inc. and Eli Lilly and Company.
Douglas W. Sborov, MD has disclosed no relevant relationships.
Jatin J. Shah, MD has received consulting fees from and has conducted contracted research for Array BioPharma, Celgene Corporation, Millennium Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Onyx Pharmaceuticals.
Ravi Vij, MD has received consulting fees from and conducted contracted research for Bristol-Myers Squibb, Celgene Corporation, Millennium Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, Inc., and Sanofi.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|
